File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Is complement a target for therapy in renal disease?

TitleIs complement a target for therapy in renal disease?
Authors
KeywordsGlomerulonephritis
Immunotherapy
Soluble CR1
Treatment
Xenotransplantation
Issue Date1998
Citation
Kidney International, 1998, v. 54 n. 5, p. 1429-1436 How to Cite?
AbstractComplement deposition in the injured kidney is common, especially in glomerulonephritis. The precise role of the complement system in the mediation of tissue injury in the kidney has been defined in recent years, and this has assumed extra importance with the recent development of specific forms of therapy directed at the complement pathway. As well as the induction of cell lysis, complement has many subtle effects on cell biology, particularly on endothelial cells. Complement components are produced locally in the kidney. Detailed studies of certain rare forms of nephritis have provided evidence that complement activation can directly cause tissue injury. Appreciation of the importance of complement in hyperacute rejection of xenotransplants has given new impetus to the development of complement inhibitors. A narrative review is provided, with a brief overview of the complement pathway and its regulatory mechanisms, mechanisms of complement- induced tissue injury, local complement production, and the renal consequences of complement dysregulation. Currently available forms of therapy aimed at the complement system are reviewed, and possible future therapeutic strategies are suggested. The complement system plays a direct causal role in tissue injury in certain forms of renal disease. Specific forms of therapy are becoming available that can selectively interrupt complement activation or promote its regulation. Much of the drive for the development of these therapies comes from the field of xenotransplantation, but these forms of therapy should also be tested in various primary renal diseases.
Persistent Identifierhttp://hdl.handle.net/10722/195349
ISSN
2023 Impact Factor: 14.8
2023 SCImago Journal Rankings: 3.886
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMathieson, PW-
dc.date.accessioned2014-02-28T06:12:01Z-
dc.date.available2014-02-28T06:12:01Z-
dc.date.issued1998-
dc.identifier.citationKidney International, 1998, v. 54 n. 5, p. 1429-1436-
dc.identifier.issn0085-2538-
dc.identifier.urihttp://hdl.handle.net/10722/195349-
dc.description.abstractComplement deposition in the injured kidney is common, especially in glomerulonephritis. The precise role of the complement system in the mediation of tissue injury in the kidney has been defined in recent years, and this has assumed extra importance with the recent development of specific forms of therapy directed at the complement pathway. As well as the induction of cell lysis, complement has many subtle effects on cell biology, particularly on endothelial cells. Complement components are produced locally in the kidney. Detailed studies of certain rare forms of nephritis have provided evidence that complement activation can directly cause tissue injury. Appreciation of the importance of complement in hyperacute rejection of xenotransplants has given new impetus to the development of complement inhibitors. A narrative review is provided, with a brief overview of the complement pathway and its regulatory mechanisms, mechanisms of complement- induced tissue injury, local complement production, and the renal consequences of complement dysregulation. Currently available forms of therapy aimed at the complement system are reviewed, and possible future therapeutic strategies are suggested. The complement system plays a direct causal role in tissue injury in certain forms of renal disease. Specific forms of therapy are becoming available that can selectively interrupt complement activation or promote its regulation. Much of the drive for the development of these therapies comes from the field of xenotransplantation, but these forms of therapy should also be tested in various primary renal diseases.-
dc.languageeng-
dc.relation.ispartofKidney International-
dc.subjectGlomerulonephritis-
dc.subjectImmunotherapy-
dc.subjectSoluble CR1-
dc.subjectTreatment-
dc.subjectXenotransplantation-
dc.titleIs complement a target for therapy in renal disease?-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1523-1755.1998.00129.x-
dc.identifier.pmid9844118-
dc.identifier.scopuseid_2-s2.0-0031727741-
dc.identifier.volume54-
dc.identifier.issue5-
dc.identifier.spage1429-
dc.identifier.epage1436-
dc.identifier.isiWOS:000076559500002-
dc.identifier.issnl0085-2538-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats